December 10, 2005
Zometa Prevents Osteoporosis in Prostate Cancer Patients
A multicenter trial has confirmed that Zometa (zoledronic acid) given for one year prevents bone loss in patients with metastatic prostate cancer who are undergoing hormone therapy. The details of this phase II study were reported in the November 2005 issue of Urology. (CancerConsultants.com)
My husband has prostate cancer. His urologist sent him for a bone density scan, it came back low. Dr. now says to have the zometa injections. What are the pros and cons of this drug?